Clinical Trial Technology Editorial

  1. In A Clinical Trial, Can Fitness Trackers Actually Track Fitness?

    Many in the clinical space have been anxiously waiting for wearable devices to make it into clinical trials. The benefits they might provide to patients can be great, and we seem to be solving problems related to privacy and data collection. But how accurate are many of the devices currently on the market?

  2. The Future Of Data And Technology In Clinical Trials

    In advance of its upcoming Data & Technology in Clinical Trials 2016 conference, eyeforpharma has released a report on the future of data and technology adoption in clinical trials. An Industry View Point: The Future of Leveraging Data & Technology in Clinical Trials takes a detailed look at the impact of data collection and analysis methods, current challenges, and patient centricity.

  3. Is Inefficient EDC Technology Holding Back The Paperless Revolution?

    When it comes to clinical trials, the pharma industry has talked about making them paperless for more than a decade. But today it remains a problem the industry seems unable to solve. “Nothing has fundamentally changed in how we conduct clinical trials,” says Ed Sequine, CEO of Clinical Ink. “We seem to be waiting for new solutions to emerge, even as we continue to do the same things over and over again.”

  4. Quintiles VP: We Must Transform Clinical Development To Meet Challenges

    Making his introductory remarks as Chairperson for the 5th Annual CROWN Congress in Philadelphia earlier this year, Martin Giblin, VP of Data Science, Safety and Regulatory Operations for Quintiles, painted a bleak view of some of the challenges currently facing the pharma industry, and what we must do to meet them.

  5. Is Outcome Switching Still A Problem In Clinical Trials?

    The scientific method is pretty straightforward. Ask a question, conduct background research, construct a hypothesis, perform an experiment to test the hypothesis, and determine if the data supports or rejects the hypothesis. Unfortunately, many are questioning whether altering the hypothesis, something known in the life sciences as outcome switching, is a problem in clinical trials.

  6. IN CASE YOU MISSED IT: Clinical Leader Top 3 Articles For February 2016

    Below are my top three articles downloaded on Clinical Leader for the month of February 2016. In case you missed them, please take this opportunity to see what everyone else was learning about protocol design and EMA recommendations surrounding the clinical tragedy in France, and biopharma trends that will impact clinical trials in 2016. 

  7. Can Sharing Clinical Notes Increase Patient Engagement And Retention?

    If patients are more engaged with a study, and take more of an ownership role in their health and data, it’s believed they will become more attached to the study and the treatment. Some pharma companies are even looking into the possibility of patients being able to review and delete their own data. But what about notes that are recorded by a physician during a patient’s visit to a clinic? Should that information also be shared with patients?

  8. Progress Made, But One-Third Of Results Still Missing
    2/24/2016 was created to inform the public of the results of clinical trials. Since the database went live in 2008, it has accumulated data on 200,000 trials in more than 170 countries. Compliance with established requirements is improving, but according to NIH data recently shared by Sen. Charles Grassley of Iowa, more than a third of applicable study results are still missing.

  9. Report: Pharma Is Most Resistant To Mobile Technology Use In Clinical Trials

    There are several technologies that promise to improve the ease and efficiency of conducting clinical trials in the future. The one that seems to hold the most potential for also easing the burden on patients, and helping sponsors with patient recruitment and retention, is mobile health technologies. But is the adoption rate of mHealth in clinical trials increasing?

  10. Clinical Outsourcing Market To See Continued Growth Through 2020

    A recent report from ISR, titled 2016 CRO Market Size Projections 2015-2020, paints an exciting and eventful future for the clinical trials market. This market has certainly been one of the best performing of late. In 2015, while the DJIA was down around 10 percent, clinical companies like PRA Health (up 78 percent), INC Research (up 64 percent) ICON (up 19 percent), Quintiles (up 6 percent), and PAREXEL (up 2 percent), all had great years.